Classification: Official
Publication reference: PRN00733

To:

• Regional:
  • Medical directors
  • Directors of primary care and public health
  • Chief pharmacists
• Integrated care board (ICB):
  • Heads of primary care
  • Pharmacy leads

Cc:

• ICB chief executives

Dear colleague,

The role of inclisiran in lipid management

Please find attached a briefing note on the role of inclisiran in support of cardiovascular disease prevention. The purpose of this is to ensure you have the latest clinical evidence regarding the prescribing of inclisiran to support lipid management in primary care, including pre-publication long-term data presented earlier this week at a late breaking session of the European Society of Cardiology (ESC) Congress 2023.

It is vital that GPs and other clinicians have access to the relevant evidence to enable them to make informed choices when prescribing lipid lowering therapies. We hope that setting out this evidence in one place will support local discussions with colleagues through relevant forums to ensure a consistent approach for patients across geographies and support us to improve cardiovascular disease prevention.

Thank you for your ongoing efforts.

Yours sincerely,

Dr Amanda Doyle, National Director for Primary Care and Community Services, NHS England.
Helen Williams, National Specialty Advisor for Cardiovascular Disease Prevention, NHS England.
Matthew Fagg, Director of Prevention NHS England.